Moderna Posts $1.2 Billion Loss as Demand For COVID Jab Collapses, Promises Investors ‘Next-Generation’ Vaccine to Tackle New Strains

The American drug company Moderna has posted a first-quarter loss of $1.2 billion after demand for their dodgy COVID-19 vaccine collapsed.

Sales of the company’s COVID-19 vaccine were a mere $167 million over the first quarter of 2024, compared with $2.8 billion over the same period last year.

The company said in its earnings report:

This decline aligns with the anticipated transition to a seasonal COVID-19 vaccine market. In the prior year period, the...